1.04 USD
-0.02 (-1.89%)
LEXX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. The financial health of LEXX is average, but there are quite some concerns on its profitability. LEXX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
LEXX had negative earnings in the past year.
In the past year LEXX has reported a negative cash flow from operations.
LEXX had negative earnings in each of the past 5 years.
LEXX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
LEXX has a Return On Assets of -168.90%. This is amonst the worse of the industry: LEXX underperforms 88.02% of its industry peers.
With a Return On Equity value of -205.08%, LEXX is not doing good in the industry: 73.44% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -168.9% | ||
| ROE | -205.08% | ||
| ROIC | N/A |
ROA(3y)-124.81%
ROA(5y)-108.73%
ROE(3y)-127.55%
ROE(5y)-113.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LEXX's Gross Margin of 99.56% is amongst the best of the industry. LEXX outperforms 97.92% of its industry peers.
In the last couple of years the Gross Margin of LEXX has grown nicely.
The Profit Margin and Operating Margin are not available for LEXX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.01%
GM growth 5Y1.71%
2. Health
2.1 Basic Checks
LEXX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LEXX has been increased compared to 1 year ago.
Compared to 5 years ago, LEXX has more shares outstanding
There is no outstanding debt for LEXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
LEXX has an Altman-Z score of -5.45. This is a bad value and indicates that LEXX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -5.45, LEXX is not doing good in the industry: 63.02% of the companies in the same industry are doing better.
LEXX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.45 |
ROIC/WACCN/A
WACC8.1%
2.3 Liquidity
LEXX has a Current Ratio of 3.90. This indicates that LEXX is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.90, LEXX perfoms like the industry average, outperforming 58.33% of the companies in the same industry.
LEXX has a Quick Ratio of 3.90. This indicates that LEXX is financially healthy and has no problem in meeting its short term obligations.
LEXX's Quick ratio of 3.90 is in line compared to the rest of the industry. LEXX outperforms 59.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.9 | ||
| Quick Ratio | 3.9 |
3. Growth
3.1 Past
The earnings per share for LEXX have decreased strongly by -50.00% in the last year.
The Revenue has grown by 61.95% in the past year. This is a very strong growth!
Measured over the past years, LEXX shows a quite strong growth in Revenue. The Revenue has been growing by 16.11% on average per year.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.54%
Revenue 1Y (TTM)61.95%
Revenue growth 3Y-13.6%
Revenue growth 5Y16.11%
Sales Q2Q%107.14%
3.2 Future
LEXX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.69% yearly.
LEXX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 181.98% yearly.
EPS Next Y-50.04%
EPS Next 2Y-7.38%
EPS Next 3Y-18.48%
EPS Next 5Y22.69%
Revenue Next Year69.94%
Revenue Next 2Y41.17%
Revenue Next 3Y52.75%
Revenue Next 5Y181.98%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LEXX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LEXX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
LEXX's earnings are expected to decrease with -18.48% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.38%
EPS Next 3Y-18.48%
5. Dividend
5.1 Amount
No dividends for LEXX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:LEXX (12/2/2025, 1:22:56 PM)
1.04
-0.02 (-1.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners11.75%
Inst Owner Change-26.67%
Ins Owners7.51%
Ins Owner Change5.43%
Market Cap23.12M
Revenue(TTM)615.90K
Net Income(TTM)-11.39M
Analysts82.5
Price Target5.44 (423.08%)
Short Float %3.13%
Short Ratio0.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.14%
Min EPS beat(2)-31.41%
Max EPS beat(2)5.12%
EPS beat(4)1
Avg EPS beat(4)-20.45%
Min EPS beat(4)-31.41%
Max EPS beat(4)5.12%
EPS beat(8)3
Avg EPS beat(8)-8.37%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)55.65%
Min Revenue beat(2)24.52%
Max Revenue beat(2)86.78%
Revenue beat(4)3
Avg Revenue beat(4)34.67%
Min Revenue beat(4)-52.94%
Max Revenue beat(4)86.78%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.11%
PT rev (3m)-11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.08%
EPS NY rev (1m)0%
EPS NY rev (3m)1.46%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 37.54 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.16 | ||
| P/tB | 4.59 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.66
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0.03
BVpS0.25
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -168.9% | ||
| ROE | -205.08% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.56% | ||
| FCFM | N/A |
ROA(3y)-124.81%
ROA(5y)-108.73%
ROE(3y)-127.55%
ROE(5y)-113.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.01%
GM growth 5Y1.71%
F-Score4
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 179.51% | ||
| Cap/Sales | 25.18% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.9 | ||
| Quick Ratio | 3.9 | ||
| Altman-Z | -5.45 |
F-Score4
WACC8.1%
ROIC/WACCN/A
Cap/Depr(3y)180.28%
Cap/Depr(5y)128.17%
Cap/Sales(3y)61.25%
Cap/Sales(5y)40.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.54%
EPS Next Y-50.04%
EPS Next 2Y-7.38%
EPS Next 3Y-18.48%
EPS Next 5Y22.69%
Revenue 1Y (TTM)61.95%
Revenue growth 3Y-13.6%
Revenue growth 5Y16.11%
Sales Q2Q%107.14%
Revenue Next Year69.94%
Revenue Next 2Y41.17%
Revenue Next 3Y52.75%
Revenue Next 5Y181.98%
EBIT growth 1Y-137.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-76.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-78.27%
OCF growth 3YN/A
OCF growth 5YN/A
LEXARIA BIOSCIENCE CORP / LEXX FAQ
Can you provide the ChartMill fundamental rating for LEXARIA BIOSCIENCE CORP?
ChartMill assigns a fundamental rating of 3 / 10 to LEXX.
Can you provide the valuation status for LEXARIA BIOSCIENCE CORP?
ChartMill assigns a valuation rating of 0 / 10 to LEXARIA BIOSCIENCE CORP (LEXX). This can be considered as Overvalued.
What is the profitability of LEXX stock?
LEXARIA BIOSCIENCE CORP (LEXX) has a profitability rating of 1 / 10.
What is the expected EPS growth for LEXARIA BIOSCIENCE CORP (LEXX) stock?
The Earnings per Share (EPS) of LEXARIA BIOSCIENCE CORP (LEXX) is expected to decline by -50.04% in the next year.